Program
Human Papillomavirus Recombinant Vaccine nonavalent
Also written as “V503”, “9vHPV Vaccine” and “9vHPV vaccine”.
Its studies are mostly in Papillomavirus Infections · Condylomata Acuminata · Uterine Cervical Neoplasms · Papilloma · Dengue, led by 5 companies.
Drug pageHuman Papillomavirus Recombinant Vaccine nonavalent: every studyMany companies study it; this page follows only the 25 they lead. All 74 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 207 open or running | phase 3since Jul 21, 2009 | Jul 21, 2009 | Jan 15, 2027phase 3 · NCT04199689 |
| Shanghai Bovax Biotechnologyits history only | 21 open or running | phase 3since Jun 8, 2020 | Jun 8, 2020 | none ahead |
| Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chairits history only | 11 open or running | early phase 1since Apr 28, 2025 | Apr 28, 2025 | none ahead |
| Takedaits history only | 10 open or running | phase 3since Mar 16, 2020 | Mar 16, 2020 | none ahead |
| Xiamen Innovax Biotechits history only | 11 open or running | phase 4since Jun 16, 2026 | Jun 16, 2026 | Feb 28, 2027phase 4 · NCT07668271 |
Also a collaborator on its studies: Chongqing Bovax Biopharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Jul 21, 2009.
- Nov 8, 2013Phase 3 study in Papillomavirus InfectionsNCT01984697 · 1,518 enrolled
- Apr 8, 2014Phase 3 study in Papillomavirus InfectionsNCT02114385 · 500 enrolled · Belgium, Germany, Netherlands
- May 16, 2017Phase 3 study in Uterine Cervical NeoplasmsNCT03158220 · 1,212 enrolled · Austria, Belgium, Finland and more
- May 23, 2018Phase 3 study in Papillomavirus InfectionsNCT03546842 · 201 enrolled · Vietnam
- Apr 3, 2019Phase 3 study in Papillomavirus InfectionsNCT03903562 · 1,990 enrolled · China
- Jun 21, 2019Phase 3 study in Papillomavirus InfectionsNCT03998254 · 6,000 enrolled · China
- Dec 12, 2019Phase 3 study in Papillomavirus InfectionsNCT04199689 · 6,033 enrolled · United States, Belgium, Brazil and more
- Nov 5, 2020Phase 3 study in Condylomata AcuminataNCT04635423 · 1,059 enrolled · Japan
- Jan 12, 2021Phase 3 study in Papillomavirus InfectionsNCT04708041 · 700 enrolled · United States, Colombia, Mexico and more
- Feb 23, 2021Phase 3 study in Papillomavirus InfectionsNCT04772534 · 314 enrolled · Japan
- Nov 10, 2021Phase 3 study in Papillomavirus InfectionsNCT05119855 · 165 enrolled · United States
- Mar 8, 20222 phase 3 studiesNCT05285826, NCT05314023
- Jun 28, 2022Phase 3 study in Papillomavirus InfectionsNCT05450705 · 1,500 enrolled · China
- Aug 21, 2026Phase 3 study in Papillomavirus InfectionsNCT07785843 · 930 planned · China
Ahead
- Jan 15, 2027Primary completion: phase 3 study in Papillomavirus InfectionsNCT04199689
- Dec 18, 2027Primary completion: phase 3 study in Papillomavirus InfectionsNCT07785843
- Mar 31, 2028Primary completion: phase 3 study in Papillomavirus InfectionsNCT03998254
- Feb 19, 2029Primary completion: phase 3 study in Condylomata AcuminataNCT05314023
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 20 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07785843Papillomavirus Infections · China | 3 | Recruiting | Dec 18, 2027 | 930 |
| NCT05450705Papillomavirus Infections · China | 3 | Active, not recruiting | Aug 3, 2029 | 1,500 |
| NCT05314023Condylomata Acuminata · China | 3 | Active, not recruiting | Feb 19, 2029 | 1,590 |
| NCT05285826Papillomavirus Infections · China | 3 | Active, not recruiting | May 25, 2029 | 8,100 |
| NCT05119855Papillomavirus Infections · United States | 3 | Completed | Dec 12, 2023 | 165 |
| NCT04772534Papillomavirus Infections · Japan | 3 | Completed | Apr 6, 2024 | 314 |
| NCT04708041Papillomavirus Infections · United States, Colombia, Mexico and more | 3 | Active, not recruiting | Oct 23, 2029 | 700 |
| NCT04635423Condylomata Acuminata · Japan | 3 | Completed | Dec 31, 2023 | 1,059 |
| NCT04199689Papillomavirus Infections · United States, Belgium, Brazil and more | 3 | Active, not recruiting | Jan 15, 2027 | 6,033 |
| NCT03998254Papillomavirus Infections · China | 3 | Active, not recruiting | Mar 31, 2028 | 6,000 |
| NCT03903562Papillomavirus Infections · China | 3 | Completed | Feb 28, 2025 | 1,990 |
| NCT03546842Papillomavirus Infections · Vietnam | 3 | Completed | Jan 29, 2019 | 201 |
| NCT03158220Uterine Cervical Neoplasms · Austria, Belgium, Finland and more | 3 | Completed | Nov 19, 2018 | 1,212 |
| NCT02114385Papillomavirus Infections · Belgium, Germany, Netherlands | 3 | Completed | Apr 22, 2015 | 500 |
| NCT01984697Papillomavirus Infections | 3 | Completed | Jun 19, 2015 | 1,518 |
| NCT01651949Condylomata Acuminata | 3 | Completed | Aug 4, 2014 | 2,520 |
| NCT01304498Human Papillomavirus | 3 | Completed | Dec 20, 2011 | 600 |
| NCT01254643Papillomavirus Infections | 3 | Completed | Aug 10, 2013 | 100 |
| NCT01047345Uterine Cervical Neoplasms | 3 | Completed | Jun 10, 2011 | 924 |
| NCT00943722Uterine Cervical Neoplasms | 3 | Completed | Apr 30, 2011 | 3,074 |
How it is read
Names in the registry
- “V503”, 10 entries
- “9vHPV Vaccine”, 5 entries
- “9vHPV vaccine”, 5 entries
- “9-valent HPV vaccine (Cecolin 9)”, 1 entry
- “9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use”, 1 entry
Conditions, from the studies’ own filings
- Papillomavirus Infections, 13 studies
- Condylomata Acuminata, 5 studies
- Uterine Cervical Neoplasms, 4 studies
- Papilloma, 1 study
- Dengue, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.